These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26771723)

  • 1. What are the potential limitations of drug coated balloons and possible ways to overcome.
    Werk M
    J Cardiovasc Surg (Torino); 2016 Feb; 57(1):23-8. PubMed ID: 26771723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What are the potential limitations of drug coated balloons (DCBs) and possible ways to overcome.
    Werk M
    J Cardiovasc Surg (Torino); 2015 Dec; ():. PubMed ID: 26681534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug coated balloons below-the-knee: just too early?
    Fanelli F; Cannavale A
    J Cardiovasc Surg (Torino); 2016 Feb; 57(1):18-22. PubMed ID: 26771722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-coated balloons: what is the evidence?
    Marques L; Hopf-Jensen S; Müller-Hülsbeck S
    J Cardiovasc Surg (Torino); 2016 Feb; 57(1):12-7. PubMed ID: 26771721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How does a drug-coated balloon work? Overview of coating techniques and their impact.
    Speck U; Stolzenburg N; Peters D; Scheller B
    J Cardiovasc Surg (Torino); 2016 Feb; 57(1):3-11. PubMed ID: 26771720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments with drug-coated balloons.
    Tepe G
    J Cardiovasc Surg (Torino); 2016 Feb; 57(1):1-2. PubMed ID: 26771719
    [No Abstract]   [Full Text] [Related]  

  • 8. Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis.
    Ju MH; Rodríguez HE
    J Cardiovasc Surg (Torino); 2012 Aug; 53(4):459-63. PubMed ID: 22854525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries.
    Freyhardt P; Zeller T; Kröncke TJ; Schwarzwaelder U; Schreiter NF; Stiepani H; Sixt S; Rastan A; Werk M
    Rofo; 2011 May; 183(5):448-55. PubMed ID: 21274828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.
    Tepe G; Zeller T; Albrecht T; Heller S; Schwarzwälder U; Beregi JP; Claussen CD; Oldenburg A; Scheller B; Speck U
    N Engl J Med; 2008 Feb; 358(7):689-99. PubMed ID: 18272892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative technologies for SFA occlusions: drug coated balloons in SFA lesions.
    Minar E; Schillinger M
    J Cardiovasc Surg (Torino); 2012 Aug; 53(4):481-6. PubMed ID: 22854528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral applications of drug-coated balloons: past, present and future.
    Krokidis M; Spiliopoulos S; Katsanos K; Sabharwal T
    Cardiovasc Intervent Radiol; 2013 Apr; 36(2):281-91. PubMed ID: 22915325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
    Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.
    Marmagkiolis K; Hakeem A; Choksi N; Al-Hawwas M; Edupuganti MM; Leesar MA; Cilingiroglu M
    Catheter Cardiovasc Interv; 2014 Oct; 84(4):555-64. PubMed ID: 24740749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
    Herten M; Torsello GB; Schönefeld E; Imm B; Osada N; Stahlhoff S
    J Vasc Surg; 2015 Feb; 61(2):394-9. PubMed ID: 25307133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Ranger drug-coated balloon: advances in drug-coated technology for treatment of femoropopliteal segment arterial disease.
    Sharma N; Finn MT; Parikh SA; Granada J
    Future Cardiol; 2023 Mar; 19(3):127-135. PubMed ID: 37334764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
    Werk M; Langner S; Reinkensmeier B; Boettcher HF; Tepe G; Dietz U; Hosten N; Hamm B; Speck U; Ricke J
    Circulation; 2008 Sep; 118(13):1358-65. PubMed ID: 18779447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine.
    Kolodgie FD; Pacheco E; Yahagi K; Mori H; Ladich E; Virmani R
    J Vasc Interv Radiol; 2016 Nov; 27(11):1676-1685.e2. PubMed ID: 27641674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Remote results of angioplasty using drug-coated balloons in lesions of the femoropopliteal segment].
    Zatevakhin II; Shipovskiĭ VN; Tursunov SB; Bagdat'ev VE; Dzhurakulov ShR
    Angiol Sosud Khir; 2014; 20(4):64-8. PubMed ID: 25490359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.